预约演示

Cancer drug from lab of bankrupt biotech works against COVID-19 and MRSA lung damage in mice

2024-07-09

临床1期

Before Infinity Pharmaceuticals shut down, eganelisib was fast-tracked by the FDA for potential use in triple-negative breast cancer in combination with other drugs.

Just inInfinity Pharmaceuticals wave to remeganelisibt SARS-CoV-2 is here to sFDA, researchers at the Utriple-negative breast cancerDiego (UCSD) have published new findings that show an experimental cancer drug developed by a now-bankrupt biotech can suppress the virus in lung tissue.

In a July 3 article in Science Translational Medicine, the UCSD team established that levels of damageUniversity of California, San Diego (UCSD) are raised in the lungs of people with COVID-19 and otcancerfections, like methicillin-resistant staphylococcus aureus (MRSA).

Targeting an enzyme called phosphatidylinositol 3,4,5-kinasUCSDmma (PI3Kγ) with the small molecule inhibitor eganelisib—a clinical-stage anti-cancer agent developed by Infinity PharmacCOVID-19, which decinfectionster 11 bankruptcy in October 2023—reduced the number of myeloid cells in the lungs and improved the survival rate of mice infected with either COVID-19 or MRSA.

“Other drugs were tested eaphosphatidylinositol 3,4,5-kinase gamma (PI3Kγ)cts, with only modest success,” Judeganelisib, Ph.D., the paper’s secanceruthor who also studiInfinity Pharmaceuticalsof Infinity, said in a press release. “Our work is significant because this is the first time this particular approach of targeting the myeloid cells specifically hCOVID-19showMRSA be effective in COVID.”

Myeloid cells release immune pathway signaCOVID-19teins called cytokines and are thus an essential part of the immune system. But the inflammation they cause can go awry aeganelisib life-threatening lung damage, as happens in some patients with COVID-19 as well as those who are co-infected with flu and MRSA.

PI3Kγ is a key component of this process because it helps myeloid cells move into virus-infected organs. It does the same thing in caninflammationes, which was the logic behind eganelisib’s mechanism of action. Stopping PI3Kγ’s activity stops myCOVID-19ll migration, ameliorating tissue damage.flu MRSA

PI3Kγe Infinity shut down, eganelisib was fast-tracked by the FDA for potential use in triple-negative breast cancer in combination with other drugs. A phase 1 study on that indeganelisibs completed in May 2024. ClinicalPI3Kγls for its use in urethral cancer, head and neck cancer and renal cell carcinoma were also underway.

Now, the team behind the reeganelisibes that it will lead drugFDAmpanies to develop comtriple-negative breast cancerto treat COVID-19, MRSA and other diseases that cause myeloid-cell-driven organ damage. Varner also said in the release that shurethral cancereshead and neck cancer to mrenal cell carcinomateam to continue their work in a range of disease settings.